Hood River Capital Management LLC Purchases 25,507 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Hood River Capital Management LLC increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 521,093 shares of the company’s stock after acquiring an additional 25,507 shares during the period. Krystal Biotech comprises about 2.0% of Hood River Capital Management LLC’s holdings, making the stock its 9th largest holding. Hood River Capital Management LLC’s holdings in Krystal Biotech were worth $95,694,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after buying an additional 35,632 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Krystal Biotech by 54.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after acquiring an additional 231,255 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Krystal Biotech by 1.3% during the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after purchasing an additional 7,537 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Krystal Biotech by 23.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company’s stock valued at $28,292,000 after purchasing an additional 43,709 shares in the last quarter. Finally, Braidwell LP grew its stake in Krystal Biotech by 153.2% in the fourth quarter. Braidwell LP now owns 196,200 shares of the company’s stock valued at $24,341,000 after purchasing an additional 118,703 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

Shares of KRYS opened at $184.17 on Monday. Krystal Biotech, Inc. has a one year low of $93.95 and a one year high of $219.34. The company’s fifty day moving average price is $195.14 and its 200 day moving average price is $179.47. The company has a market capitalization of $5.26 billion, a PE ratio of 98.49 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The firm had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.25) EPS. Analysts anticipate that Krystal Biotech, Inc. will post 3.13 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Evercore ISI lifted their price target on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. HC Wainwright raised their price target on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Finally, Chardan Capital upped their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Krystal Biotech currently has an average rating of “Buy” and an average price target of $196.75.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).